

Duane Burton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2091679/publications.pdf>

Version: 2024-02-01

38
papers

1,205
citations

331259

21
h-index

377514

34
g-index

38
all docs

38
docs citations

38
times ranked

1087
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea. <i>Gut</i> , 2023, 72, 54-65.	6.1	16
2	Fasting pyloric diameter and distensibility by functional endoluminal imaging probe in unselected healthy volunteers. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14386.	1.6	8
3	Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic. <i>Obesity</i> , 2021, 29, 662-671.	1.5	70
4	Association of gastric emptying with postprandial appetite and satiety sensations in obesity. <i>Obesity</i> , 2021, 29, 1497-1507.	1.5	13
5	Intestinal chemosensitivity in irritable bowel syndrome associates with small intestinal TRPV channel expression. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1179-1192.	1.9	17
6	Randomised study: effects of the 5-HT ₄ receptor agonist fencisetrag vs placebo on gut transit in patients with gastroparesis. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1010-1020.	1.9	21
7	Editorial: understanding IBS pathophysiology through “converging channels of research” authors™ reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1215-1216.	1.9	0
8	Utility of the plasma pancreatic polypeptide response to modified sham feeding in diabetic gastroenteropathy and non-ulcer dyspepsia. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13744.	1.6	5
9	Randomised clinical trial: significant biochemical and colonic transit effects of the farnesoid X receptor agonist tropifexor in patients with primary bile acid diarrhoea. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 808-820.	1.9	30
10	Physical activity is associated with accelerated gastric emptying and increased ghrelin in obesity. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13879.	1.6	10
11	Expanding criteria for slow colonic transit in patients being evaluated for chronic constipation by scintigraphy. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13878.	1.6	9
12	Effects of Colesevelam on Bowel Symptoms, Biomarkers, and Colonic Mucosal Gene Expression in Patients With Bile Acid Diarrhea in a Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2962-2970.e6.	2.4	27
13	Ileo-colonic delivery of conjugated bile acids improves glucose homeostasis via colonic GLP-1-producing enteroendocrine cells in human obesity and diabetes. <i>EBioMedicine</i> , 2020, 55, 102759.	2.7	43
14	Secretin effects on gastric functions, hormones and symptoms in functional dyspepsia and health: randomized crossover trial. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G635-G645.	1.6	8
15	Relationship between symptoms during a gastric emptying study and intestinal chemosensitivity with daily symptoms. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13686.	1.6	14
16	Increased fecal primary bile acids in multiple myeloma with engraftment syndrome diarrhea after stem cell transplant. <i>Bone Marrow Transplantation</i> , 2019, 54, 1898-1907.	1.3	1
17	GI Dysfunctions in Diabetic Gastroenteropathy, Their Relationships With Symptoms, and Effects of a GLP-1 Antagonist. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1967-1977.	1.8	16
18	Gastric accommodation measurements by single photon emission computed tomography and two-dimensional scintigraphy in diabetic patients with upper gastrointestinal symptoms. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13581.	1.6	19

#	ARTICLE	IF	CITATIONS
19	Bile and fat excretion are biomarkers of clinically significant diarrhoea and constipation in irritable bowel syndrome. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 744-758.	1.9	32
20	Aquaporin Expression in Colonic Mucosal Biopsies From Irritable Bowel Syndrome With Diarrhea. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00019.	1.3	22
21	Analysis of Fecal Primary Bile Acids Detects Increased Stool Weight and Colonic Transit in Patients With Chronic Functional Diarrhea. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 922-929.e2.	2.4	42
22	Open: Effects of NGM282, an FGF19 variant, on colonic transit and bowel function in functional constipation: a randomized phase 2 trial. <i>American Journal of Gastroenterology</i> , 2018, 113, 725-734.	0.2	29
23	Bile Acid Deficiency in a Subgroup of Patients With Irritable Bowel Syndrome With Constipation Based on Biomarkers in Serum and Fecal Samples. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 522-527.	2.4	57
24	Potential mechanisms of effects of serum-derived bovine immunoglobulin/protein isolate therapy in patients with diarrhea-predominant irritable bowel syndrome. <i>Physiological Reports</i> , 2017, 5, e13170.	0.7	24
25	Gastric Motor Dysfunction in Patients With Functional Gastrointestinal Symptoms. <i>American Journal of Gastroenterology</i> , 2017, 112, 1689-1699.	0.2	67
26	Effects of NK1 receptors on gastric motor functions and satiation in healthy humans: results from a controlled trial with the NK1 antagonist aprepitant. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, G505-G510.	1.6	44
27	Relationship of gastric emptying or accommodation with satiation, satiety, and postprandial symptoms in health. <i>American Journal of Physiology - Renal Physiology</i> , 2017, 313, G442-G447.	1.6	38
28	Gluten-induced symptoms in diarrhea-predominant irritable bowel syndrome are associated with increased myosin light chain kinase activity and claudin-15 expression. <i>Laboratory Investigation</i> , 2017, 97, 14-23.	1.7	43
29	Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome—Diarrhea Without Bile Acid Malabsorption. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 720-727.e1.	2.4	43
30	Regional Colonic Transit Pattern Does Not Conclusively Identify Evacuation Disorders in Constipated Patients with Delayed Colonic Transit. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 92-100.	0.8	8
31	Short-Term Effects of Relamorelin on Descending Colon Motility in Chronic Constipation: A Randomized, Controlled Trial. <i>Digestive Diseases and Sciences</i> , 2016, 61, 852-860.	1.1	27
32	Acute Effects of a Glucagon-Like Peptide 2 Analogue, Teduglutide, on Gastrointestinal Motor Function and Permeability in Adult Patients With Short Bowel Syndrome on Home Parenteral Nutrition. <i>Journal of Parenteral and Enteral Nutrition</i> , 2016, 40, 1089-1095.	1.3	27
33	A Randomized Trial of 5-Hydroxytryptamine ₄ Receptor Agonist, YKP10811, on Colonic Transit and Bowel Function in Functional Constipation. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 701-708.e1.	2.4	25
34	Relamorelin Relieves Constipation and Accelerates Colonic Transit in a Phase 2, Placebo-Controlled, Randomized Trial. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2312-2319.e1.	2.4	39
35	Pilot trial: Pregabalin on colonic sensorimotor functions in irritable bowel syndrome. <i>Digestive and Liver Disease</i> , 2014, 46, 113-118.	0.4	4
36	Bowel Functions, Fecal Unconjugated Primary and Secondary Bile Acids, and Colonic Transit in Patients With Irritable Bowel Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1270-1275.e1.	2.4	132

#	ARTICLE	IF	CITATIONS
37	Pharmacodynamic and Clinical Endpoints for Functional Colonic Disorders: Statistical Considerations. <i>Digestive Diseases and Sciences</i> , 2012, 58, 509-18.	1.1	21
38	Chenodeoxycholate in Females With Irritable Bowel Syndrome-Constipation: A Pharmacodynamic and Pharmacogenetic Analysis. <i>Gastroenterology</i> , 2010, 139, 1549-1558.e1.	0.6	154